Geschäftskunden Kundenprogramme

KI-Beratung Beta
Vor Ort
Merkzettel Warenkorb
Produktbild: Principles of Translational Science in Medicine

Principles of Translational Science in Medicine From Bench to Bedside

Fr. 173.00

inkl. gesetzl. MwSt., Versandkostenfrei

Beschreibung

Produktdetails

Einband

Gebundene Ausgabe

Erscheinungsdatum

22.07.2021

Abbildungen

105 illustrations (40 in full color)

Herausgeber

Martin Wehling

Verlag

Elsevier Science & Technology

Seitenzahl

494

Maße (L/B/H)

28.5/21.8/2.8 cm

Gewicht

1590 g

Auflage

3rd edition

Sprache

Englisch

ISBN

978-0-12-820493-1

Beschreibung

Portrait

Martin Wehling is the Managing Director at the Institute of Experimental and Clinical Pharmacology and Toxicology. Martin Wehling is Director in Clinical Pharmacology at Mannheim Medical Faculty, Mannheim University of Heidelberg, Mannheim, Germany.

Produktdetails

Einband

Gebundene Ausgabe

Erscheinungsdatum

22.07.2021

Abbildungen

105 illustrations (40 in full color)

Herausgeber

Martin Wehling

Verlag

Elsevier Science & Technology

Seitenzahl

494

Maße (L/B/H)

28.5/21.8/2.8 cm

Gewicht

1590 g

Auflage

3rd edition

Sprache

Englisch

ISBN

978-0-12-820493-1

Herstelleradresse

Libri GmbH
Europaallee 1
36244 Bad Hersfeld
DE

Email: gpsr@libri.de

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)
Die Leseprobe wird geladen.
  • Produktbild: Principles of Translational Science in Medicine

  • Part I: Introduction
    1. Introduction and definitions
    2. Problems, challenges, and initiatives in translation
    Part II. Target identification and validation
    3. "Omics? translation: a challenge for laboratory medicine
    4. The power of genomics, metabolomics, and other omics for target identification and validation
    5. Potency analysis of cellular therapies: the role of molecular assays
    6. Translational pharmacogenetics: pharmacogenetically driven clinical decision making
    7. Tissue biobanks
    8. Animal models: value and translational potency
    9. Biomarkers in the context of health authorities and consortia
    10. Human studies as a source of target information
    11. Target profiling in terms of translatability and early translation planning
    Part III. Biomarkers as key elements of successful translation
    12. Biomarkers
    13. Genetics, molecular biomarkers, and artificial intelligence to improve diagnostic and prognostic efficacy
    14. Cardiovascular translational biomarkers: translational aspects of hypertension, atherosclerosis, and heart failure in drug development in the digital era
    15. Biomarkers in oncology
    16. Translational medicine in psychiatry: challenges and imaging biomarkers
    Part IV: Early clinical trial design
    17. Methodological studies
    18. The pharmaceutical research and development productivity crisis: can exploratory clinical studies be of any help?
    19. Adaptive trial design
    20. Combining regulatory and exploratory trials
    21. Accelerating proof of concept by smart early clinical trials
    Part V: Toxicology in translation
    22. Pharmaceutical toxicology
    23. Translational safety medicine
    Part VI: Special topics in translation
    24. Cancer vaccines: translational strategies
    25. Translational aspects of biologicals: monoclonal antibodies and antibody-drug conjugates as examples
    26. Orphan drugs: why is translation so successful?
    Part VII: Biostatistics and modelling
    27. Translational science biostatistics
    28. Computational biology and model-based approaches in translational medicine
    Part VIII. Legal aspects and special interest groups
    29. Intellectual property and innovation in translational medicine
    30. Translational research in the fastest-growing population: older adults
    Part IX. Integration and application of translational guidance
    31. Translational medicine: the changing role of big pharma
    32. Translational science in medicine: putting the pieces together-biomarkers, early human trials, networking, and translatability assessment
    33. Learning by experience